|
Genetic heterogeneity and survival among pancreatic adenocarcinoma (PDAC) patients with positive family history. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Aduro Biotech (Inst); Genentech (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); PRISM BioLab (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
| |
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
| |
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Procter & Gamble |